Felix Hernandez, Javier Diaz Nido, Jesus Avila and Nieves Villanueva Pages 1024 - 1029 ( 6 )
This review describes, briefly, the characteristics and regulation of glycogen synthase kinase 3 (GSK3) together with the role of GSK3 dysfunctions in different pathologies, and GSK3 as target for therapeutic treatment in different diseases. Several GSK3 inhibitors acting at different levels are described in this work, ranging from cations like lithium to small compounds developed by different pharmaceutical companies. Also, the use of specific interference RNA (iRNA) for the specific inhibition of the expression of the different GSK3 isoforms is discussed.
GSK3, lithium, Alzheimer, neurodegeneration
Centro de Biologia Molecular “Severo Ochoa”, Universidad Autonoma de Madrid, C/Nicolas Cabrera, 1, 28049 Cantoblanco, Madrid, Spain.